10,996 Followers on Owler

Boehringer Ingelheim

Boehringer Ingelheim is a pharmaceutical company that develops, manufactures and commercializes prescription medicines and animal healthcare products. Read more

Hubertus von Baumbach's photo - Chairman of Boehringer Ingelheim

Chairman

Hubertus von Baumbach

CEO Approval Rating

76/100

Founded:

1885

Status:

PrivateIndependent Company

BOEHRINGER INGELHEIM TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

Bayer is the top competitor of Boehringer Ingelheim. Bayer is headquartered in Leverkusen, North Rhine-Westphalia, and was founded in 1863. Bayer competes in the Medical Research & Laboratories field. Bayer generates 178% the revenue of Boehringer Ingelheim.

Merck KGaA is perceived as one of Boehringer Ingelheim's biggest rivals. Merck KGaA was founded in Darmstadt, Other} in 1668. Like Boehringer Ingelheim, Merck KGaA also operates in the Pharmaceuticals industry. Compared to Boehringer Ingelheim, Merck KGaA generates $7B less revenue.

Sanofi is seen as one of Boehringer Ingelheim's top competitors. Sanofi is a Public company that was founded in Paris, Île-de-France in 1994. Like Boehringer Ingelheim, Sanofi also works within the Pharmaceuticals industry. Sanofi has 47,468 more employees vs. Boehringer Ingelheim.

Weigh-in!

Help the Owler community know more

Growth Score - 1/1

Is $28.6B a good estimate for Boehringer Ingelheim's revenue?

Boehringer Ingelheim Acquisitions

COMPANY ACQUIRED
ACQUISITION DATE
AMOUNT
DESCRIPTION
NBE-Therapeutics AG

Dec 2020

Source »
$1.4B
NBE Therapeutics is a biotechnology company that develops and commercializes antibody-drug conjugates for the treatment of cancer.
Labor Dr. Merk & Kollegen GmbH

Dec 2020

Source »
undisclosed
LaborDr.Merk is a biotechnology firm that develops and commercializes oncolytic viral therapeutics for the treatment of cancer.
Global Stem cell Technology NV

Jul 2020

Source »
undisclosed
GST is a biotechnology company that develops blood-derived mesenchymal stem cells to treat orthopedic and metabolic diseases in animals.
Northern Biologics, Inc.

May 2020

Source »
undisclosed
Northern Biologics designs and develops antibody therapeutics for oncology treatments.
Amal Therapeutics SA

Jul 2019

Source »
$253.5M
Amal Therapeutics develops and commercializes peptide-based therapeutic vaccines for the treatment of cancer.

These are all the companies that Boehringer Ingelheim has acquired. Boehringer Ingelheim has acquired 9 companies and its latest acquisition was NBE-Therapeutics AG in Dec 2020. NBE Therapeutics is a biotechnology company that develops and commercializes antibody-drug conjugates for the treatment of cancer.

Boehringer Ingelheim Funding History

No recent funding data found related to Boehringer Ingelheim

Boehringer Ingelheim Investments

COMPANY

DESCRIPTION

AMOUNT

INVESTMENT DATE

ROUND

EXIT DATE

Actym Therapeutics is an immuno-oncology company that researches and develops immunotherapies for the treatment of cancer.
$34M
Apr 26, 2020
Series A
-
HepaRegeniX is a developer of clinical-stage novel therapy for the treatment of acute and chronic liver diseases.
$12.2M
Jan 20, 2020
Series B
-
Eyevensys is a biotechnology company that develops and commercializes novel therapies for the treatment of ophthalmic diseases.
$30M
Jan 07, 2020
Series B
-
Metabomed is a biotechnology company that discovers, develops and commercializes small molecule drugs for the treatment of cancer.
$12.5M
Dec 18, 2019
Equity
-
Abalos Therapeutics is a biotechnology company that develops drugs for tumors and cancer.
$13M
Oct 14, 2019
Series A
-

These are all the companies that Boehringer Ingelheim has invested in. Boehringer Ingelheim has invested 9 companies and its latest investment was NBE-Therapeutics AG in Dec 2020. NBE Therapeutics is a biotechnology company that develops and commercializes antibody-drug conjugates for the treatment of cancer.

Boehringer Ingelheim News

June 11, 2021PharmiWeb

Boehringer Ingelheim is a Founding Member of QUTAC

Ten leading German companies form this newly created Quantum Technology and Application Consortium To... See more »
June 11, 2021Pharmabiz

Boehringer Ingelheim, Lifebit Biotech partner to detect global infectious disease outbreaks

Boehringer Ingelheim, a global leader in animal health, announces the beginning of a long─term partne... See more »
June 4, 2021Pharmabiz

US FDA grants fast track designation to Boehringer Ingelheim & Zealand Pharma's GLP1/glucagon dual agonist, BI 456906 to treat NASH

Boehringer Ingelheim and Zealand Pharma A/S, a biotechnology company, announced that the US Food and ... See more »
May 28, 2021MarketScreener

Boehringer's BI 425809 has potential to address cognitive impairment in schizophrenia market, says GlobalData

(marketscreener.com) 28 May 2021 Boehringer's BI 425809 has potential to address cognitive impairment... See more »
May 27, 2021Manufacturing Chemist

Novatek requalifies as Boehringer Ingelheim approved supplier

The company†s products are designed to assist in managing critical aspects of a quality-controlled ... See more »
May 27, 2021BW BUSINESSWORLD

Lupin Receives USD 50 Million From Boehringer Ingelheim For Achievement Of Key Milestones

Lupin said its new chemical entity research team is focused on building a pipeline of highly differen... See more »
May 26, 2021BW BUSINESSWORLD

Boehringer Ingelheim India Launches Single-Shot Poultry Vaccine In India

The VAXXITEK HVT+IBD vaccine protects against two major immunosuppressive diseases -- Infectious Burs... See more »

Boehringer Ingelheim Blogs

April 23, 2014BOEHRINGER INGELHEIM GMBH BLOG

Boehringer Ingelheim Receives Two Top Diversity Awards

March 27, 2014BOEHRINGER INGELHEIM GMBH BLOG

Increasing Social Media Savvy

Boehringer Ingelheim Press Releases

March 31, 2021PRcom

Boehringer Ingelheim to Work with Xybion's Preclinical Gold Standard Solution, Pristima XD, to Enhance Lab Operations

Xybion's Preclinical Gold Standard Pristima XD Unifies and Enhances Laboratory Efficiency and Data In... See more »
March 30, 2021Cision Canada

Aservo EquiHaler , industry-first therapy for severe equine asthma, now available in Canada

/CNW/ - Boehringer Ingelheim Animal Health Canada Inc. has been granted marketing authorization for A... See more »
March 4, 2021Cision Canada

OFEV (nintedanib) receives positive recommendation from CADTH and INESSS for the treatment of progressive fibrosing interstitial lung diseases (PF-ILD)

/CNW/ - Boehringer Ingelheim (Canada) Ltd. is pleased to announce positive recommendations from the C... See more »
January 13, 2021PR Newswire

Boehringer Ingelheim Animal Health Announces U.S. Leadership Transition

/PRNewswire/ -- Boehringer Ingelheim Animal Health, a leading provider of medicine for pets, horses a... See more »
December 21, 2020Korea Newswire

New SARS-CoV-2 Neutralizing Antibody enters Clinical Phase

Cologne University Hospital (UKK), University of Marburg (UMR), the German Center for Infection Resea... See more »

Boehringer Ingelheim Videos

February 2, 2021Boehringer Ingelheim Youtube Channel

"Virtuelle Werkfhrung Boehringer Ingelheim" on YOUTUBE

January 28, 2021Boehringer Ingelheim Youtube Channel

"Interconnected Heart, Kidney and Metabolic Systems" on YOUTUBE

January 27, 2021Boehringer Ingelheim Youtube Channel

"The History of Boehringer Ingelheim (short)" on YOUTUBE

January 20, 2021Boehringer Ingelheim Youtube Channel

"Our Pharmaceutical Production" on YOUTUBE

Social Media

Boehringer Ingelheim Headquarters

Binger Strasse 173

Ingelheim am Rhein, Rhineland-Palatinate55216

49-6132-77-0

Driving Directions »

Trending Companies

Boehringer Ingelheim Summary

ABOUT

Overview

Boehringer Ingelheim is a pharmaceutical company that develops, manufactures and commercializes prescription medicines and animal healthcare products. Boehringer Ingelheim was founded in 1885. Boehringer Ingelheim's headquarters is located in Ingelhei...

CEO

Boehringer Ingelheim's Chairman, Hubertus von Baumbach, currently has an approval rating of 76%. Boehringer Ingelheim's primary competitors are Bayer, Merck KGaA & Sanofi.

Frequently Asked Questions about Boehringer Ingelheim

  1. When was Boehringer Ingelheim founded?

    Boehringer Ingelheim was founded in 1885
  2. Who is Boehringer Ingelheim's CEO?

    Boehringer Ingelheim's CEO is Hubertus von Baumbach
  3. How much revenue does Boehringer Ingelheim generate?

    Boehringer Ingelheim generates $28.6B in revenue
  4. How much funding does Boehringer Ingelheim have?

    Boehringer Ingelheim has historically raised $0 in funding
  5. Where is Boehringer Ingelheim's headquarters?

    Boehringer Ingelheim's headquarters is in Ingelheim am Rhein Rhineland-Palatinate, DE
  1. How many employees does Boehringer Ingelheim have?

    Boehringer Ingelheim has 51,944 employees
  2. What sector does Boehringer Ingelheim operate in?

    Boehringer Ingelheim is in Pharmaceuticals
  3. Who are Boehringer Ingelheim's competitors?

    Boehringer Ingelheim's top competitors are Bayer, Merck KGaA, Sanofi
  4. Who has Boehringer Ingelheim invested in?

    Boehringer Ingelheim's has invested in companies such as Actym Therapeutics, HepaRegeniX, Eyevensys